​

Nurix Therapeutics (NRIX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

NRIX Stock Forecast

Nurix Therapeutics (NRIX) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $35.58, with a high of $45.00 and a low of $31.00. This represents a 39.47% increase from the last price of $25.51.

$10 $17 $24 $31 $38 $45 High: $45 Avg: $35.58 Low: $31 Last Closed Price: $25.51

NRIX Stock Rating

Nurix Therapeutics stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 19 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 19 Strong Sell Sell Hold Buy Strong Buy

NRIX Price Target Upside V Benchmarks

TypeNameUpside
StockNurix Therapeutics39.47%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts6728
Avg Price Target$35.50$35.86$33.39
Last Closing Price$25.51$25.51$25.51
Upside/Downside39.16%40.57%30.89%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26581--14
Sep, 265101--16
Aug, 26591--15
Jul, 265101--16
Jun, 26512---17
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 16, 2026H.C. Wainwright$36.00$24.9544.29%41.12%
Oct 13, 2026Gregory RenzaTruist Financial$33.00$22.4047.32%29.36%
Oct 13, 2026Brian AbrahamsRBC Capital$35.00$22.1657.94%37.20%
Oct 13, 2026Oppenheimer$32.00$22.1644.40%25.44%
Oct 13, 2026Robert W. Baird$36.00$22.1662.45%41.12%
Oct 13, 2026Stifel Nicolaus$41.00$22.1685.02%60.72%
Jul 28, 2026Morgan Stanley$38.00$23.4362.19%48.96%
Jul 22, 2026UBS$31.00$23.4832.03%21.52%
Jul 13, 2026Joseph CatanzaroMizuho Securities$34.00$23.0647.44%33.28%
Jul 10, 2026RBC Capital$33.00$22.3347.78%29.36%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 16, 2026H.C. WainwrightBuyBuyhold
Oct 13, 2026Huber ResearchUnderweightdowngrade
Oct 13, 2026RBC CapitalOutperformOutperformhold
Oct 13, 2026OppenheimerOutperformOutperformhold
Jul 28, 2026Morgan StanleyOverweightOverweighthold
Jul 22, 2026UBSBuyBuyhold
Jul 10, 2026RBC CapitalOutperformOutperformhold
Jul 10, 2026H.C. WainwrightBuyBuyhold
Jun 11, 2026H.C. WainwrightBuyBuyhold
Jun 09, 2026UBSBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 $2 Nov 21 Nov 22 Nov 23 Nov 24 Nov 25 Nov 26 Nov 27 Nov 28 Nov 29
Nov 21Nov 22Nov 23Nov 24Nov 25Nov 26Nov 27Nov 28Nov 29
Reported$-2.73$-3.71$-2.65$-2.88$-3.05----
Avg Forecast$-2.54$0.59$-2.34$-2.81$-3.14$-3.37$-3.44$-2.45$-0.03
High Forecast$-1.81$1.55$-1.49$-2.61$-2.21$-1.82$-1.77$-1.51$-0.02
Low Forecast$-3.40$-0.38$-2.94$-3.04$-3.78$-4.53$-4.71$-4.76$-0.07
Surprise %7.48%-728.81%13.25%2.49%-2.87%----

Revenue Forecast

$0 $190M $380M $570M $760M $950M Nov 21 Nov 22 Nov 23 Nov 24 Nov 25 Nov 26 Nov 27 Nov 28 Nov 29
Nov 21Nov 22Nov 23Nov 24Nov 25Nov 26Nov 27Nov 28Nov 29
Reported$29.75M$38.63M$76.99M$54.55M$83.98M----
Avg Forecast$35.21M$47.31M$94.04M$54.58M$57.44M$71.12M$100.48M$245.89M$536.49M
High Forecast$44.28M$56.78M$140.13M$64.72M$68.99M$147.28M$104.54M$424.06M$925.25M
Low Forecast$27.43M$37.85M$68.35M$41.35M$47.20M$44.47M$96.42M$172.97M$377.40M
Surprise %-15.50%-18.36%-18.14%-0.05%46.22%----

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Nov 21 Nov 22 Nov 23 Nov 24 Nov 25 Nov 26 Nov 27 Nov 28 Nov 29
Nov 21Nov 22Nov 23Nov 24Nov 25Nov 26Nov 27Nov 28Nov 29
Reported$-117.19M$-180.36M$-143.95M$-193.57M$-264.46M----
Avg Forecast$-98.03M$-226.20M$-143.95M$-193.57M$-200.83M$-291.81M$-314.78M$-164.44M$-2.30M
High Forecast$-78.43M$-180.96M$-115.16M$-175.17M$-148.02M$-121.87M$-118.75M$-101.05M$-1.41M
Low Forecast$-117.64M$-271.43M$-172.74M$-204.03M$-253.65M$-303.86M$-316.43M$-319.36M$-4.47M
Surprise %19.55%-20.26%--31.68%----

NRIX Forecast FAQ

Is Nurix Therapeutics stock a buy?

Nurix Therapeutics stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 19 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Nurix Therapeutics is a favorable investment for most analysts.

What is Nurix Therapeutics's price target?

Nurix Therapeutics's price target, set by 19 Wall Street analysts, averages $35.58 over the next 12 months. The price target range spans from $31 at the low end to $45 at the high end, suggesting a potential 39.47% change from the previous closing price of $25.51.

How does Nurix Therapeutics stock forecast compare to its benchmarks?

Nurix Therapeutics's stock forecast shows a 39.47% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Nurix Therapeutics over the past three months?

  • October 2026: 35.71% Strong Buy, 57.14% Buy, 7.14% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 31.25% Strong Buy, 62.50% Buy, 6.25% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 33.33% Strong Buy, 60.00% Buy, 6.67% Hold, 0% Sell, 0% Strong Sell.

What is Nurix Therapeutics’s EPS forecast?

Nurix Therapeutics's average annual EPS forecast for its fiscal year ending in November 2026 is $-3.37, marking a 10.49% increase from the reported $-3.05 in 2025. Estimates for the following years are $-3.44 in 2027, $-2.45 in 2028, and $-0.03 in 2029.

What is Nurix Therapeutics’s revenue forecast?

Nurix Therapeutics's average annual revenue forecast for its fiscal year ending in November 2026 is $71.12M, reflecting a -15.31% decrease from the reported $83.98M in 2025. The forecast for 2027 is $100.48M, followed by $245.89M for 2028, and $536.49M for 2029.

What is Nurix Therapeutics’s net income forecast?

Nurix Therapeutics's net income forecast for the fiscal year ending in November 2026 stands at $-292M, representing an 10.34% increase from the reported $-264M in 2025. Projections indicate $-315M in 2027, $-164M in 2028, and $-2.301M in 2029.